Malta - English - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - gemcitabine - concentrate for solution for infusion - gemcitabine - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - gemcitabine - concentrate for soln for inf - 40 mg/ml

Canada - English - Health Canada

mega-lab manufacturing co ltd - o-phenylphenol; p-tert-pentylphenol; alcohol anhydrous - aerosol - 0.10%; 0.03%; 53.72% - o-phenylphenol 0.10%; p-tert-pentylphenol 0.03%; alcohol anhydrous 53.72% - disinfectants (for agents used on object)

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - amoxicillin 200mg,clavulanic acid 28mg - dafraclav® is indicated in the treatment of the following in­fections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis), due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections, due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections, due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - amoxicillin + clavulanic acid - amoxicillin 400mg,clavulanic acid 57mg - dafraclav is indicated in the treatment of the following infections caused by the microorganisms indicated below. - upper respiratory tract infections (including otitis media and sinusitis), due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. - lower respiratory tract infections, due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. - skin and skin structure infections, due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. - urinary tract infections. since dafraclav contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav, such an infection can be treated by the administration of dafraclav alone, addition of another antibiotic is not required.

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - tablets - amoxillin 500mg, clavulanic acid 125mg - dafraclav® is indicated in the treatment of the following infections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis) due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

Singapore - English - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - cardiovascular - intended for repair of pericardial structures and for use as a prosthesis for the surgical repair of soft tissue deficiencies, which include: defects of the abdominal and thoracis wall, hernias (including diaphragmatic, femoral, incisional, inguinal, lumbar, paracolostomy, scrotal, and umbilical) and intracardiac and great vessel repair.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferno australia pty ltd - 34082 - dressing, hydrogel - once applied, burnshields intended purpose is to protect against infection,minimise trauma and skin damage and to cool and soothe the effected area.

Australia - English - Department of Health (Therapeutic Goods Administration)

sentry medical pty ltd - 34082 - dressing, hydrogel - a sterile covering intended to cool and sooth burn site thus minimise skin damage and to protect it from infection and trauma.